Beat Acute Myeloid Leukemia (AML) 1.0

Description

Beat AML 1.0 is a collaborative research program involving 11 academic medical centers who worked collectively to better understand drugs and drug combinations that should be prioritized for further development within clinical and/or molecular subsets of acute myeloid leukemia (AML) patients. Beat AML 1.0 provides the largest-to-date dataset on primary acute myeloid leukemia samples offering genomic, clinical, and drug response.This dataset contains open Clinical Supplement and RNA-Seq Gene Expression Quantification data.This dataset also contains controlled Whole Exome Sequencing (WXS) and RNA-Seq Aligned Reads, WXS Annotated Somatic Mutation, WXS Raw Somatic Mutation, and RNA-Seq Splice Junction Quantification

Update Frequency

Genomic Data Commons (GDC) is source of truth for this dataset; GDC offers monthly data releases, although this dataset may not be updated at every release.

License

NIH Genomic Data Sharing Policy: https://gdc.cancer.gov/access-data/data-access-policies

Documentation

https://www.cancer.gov/about-nci/organization/ccg/blog/2019/beataml

Managed By

See all datasets managed by Center for Translational Data Science at The University of Chicago.

Contact

dcf-support@datacommons.io

How to Cite

Beat Acute Myeloid Leukemia (AML) 1.0 was accessed on DATE from https://registry.opendata.aws/beataml.

Usage Examples

Tools & Applications

• Genomic Data Commons by National Cancer Institute
  

Publications

• Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms by Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, et al.
  
• Functional Genomic Landscape of Acute Myeloid Leukemia by Jeffrey W. Tyner, Cristina E. Tognon, Dan Bottomly et al.